Back to journals
Academic Journal

Neuroethics

3 Papers Indexed in Blossom

Data updated

Research Footprint

Neuroethics has 3 tracked papers indexed in Blossom (2023–2024) from 14 authors, across Equity and Ethics, Anxiety Disorders and Palliative & End-of-Life Distress.

Published Papers

Open Accessindividual

A Transformative Trip? Experiences of Psychedelic Use

Analysing interviews with 26 retreat participants, the study finds that psychedelic experiences can constitute transformative experiences: 20 participants reported insights seemingly inaccessible without psychedelics and 25 of 26 reported changes in identity, values, desires or behaviour (behavioural change was most common). The authors argue this raises neuroethical concerns about consent and moral psychopharmacology and call for person-centred research and ethical inquiry.

Published
Journal
Neuroethics
Authors
Neitzke-Spruill, L., Beit, C., Robinson, J., Blevins, K., Reyno, J., Evans, N. G., Mcguire, A. L., Reynolds, J.
Open Accessindividual

How Do Psychedelics Reduce Fear of Death?

The paper argues that psychedelic experiences reduce fear of death primarily by inducing non‑physicalist metaphysical belief change rather than by purely psychological or physiological mechanisms. This finding supports the REBUS model of psychedelic therapy and challenges "neuroexistentialist" aims to naturalise spirituality, since the benefits seem to depend on persuading people away from a broadly naturalistic worldview.

Published
Journal
Neuroethics
Authors
Letheby, C.
Open Accessmeta

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research

This perspective article (2023) discusses the ethical considerations of providing post-trial access (PTA) in psychedelic clinical trials. It highlights the unique aspects of psychedelic trials, such as the legal status of psychedelics, the researcher-participant relationship, and the extended therapeutic process, as factors supporting the case for introducing PTA. The authors also advocate for a broader focus on post-trial care beyond access and provide an overview of potential provisions for psychedelic clinical trials, emphasizing the development of infrastructure for the post-legalisation psychedelic medicine ecosystem.

Published
Journal
Neuroethics
Authors
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D., Spriggs, M. J.

Quick Facts

Papers Indexed
3
h-Index
42
Open Access
No
Publisher
Springer Nature
Country
Netherlands
Website
Visit